Diatherix Eurofins launches SARS-CoV-2 virus identification for the COVID-19 respiratory infection

HUNTSVILLE, Ala., March 16, 2020 /PRNewswire/ -- As a leader in respiratory viral and bacterial testing, Diatherix Eurofins is excited to announce it has developed a test for the SARS-CoV-2 virus, the cause of the COVID-19 respiratory infection, as part of its proprietary respiratory testing portfolio. Diatherix will begin accepting specimens for testing as of March 17, 2020.

Recognizing that the Center for Disease Control and Prevention (CDC) encourages clinicians to test for multiple causes of respiratory illness, Diatherix continues to provide testing solutions that are practical, expeditious and affordable.  Specifically, Diatherix has developed the new COVID-19 Panel which includes the SARS-CoV-2 virus along with five bacterial pathogens which are known to be more prevalent and relevant to the severity of complications in both upper and lower respiratory tract infections. Further, to simplify collection for healthcare practitioners, Diatherix is ready to receive respiratory specimens, such as nasopharyngeal specimen collection methods and sputum specimen swabs. Finally, all testing will be performed pursuant to Diatherix's standard turnaround times – test results will be provided back to clinicians the same day Diatherix receives the specimen.

With Diatherix's COVID-19 Panel, clinicians will gain the ability to confirm the presence of SARS-CoV-2 along with additional diagnostic information of synergistic bacteria. These bacterial pathogens include Chlamydophila pneumoniae, Haemophilus influenzae, including Haemophilus influenzae (type B), Moraxella catarrhalis, Mycoplasma pneumoniae, and Streptococcus pneumoniae, which are also known to exacerbate the recovery for high-risk patients.

Diatherix is pleased to leverage its respiratory and infectious disease expertise to help clinicians respond to the impact of the 2019 novel coronavirus. Diatherix's testing solution will be available through other Eurofins U.S. clinical laboratories as well, including Boston Heart Diagnostics and EGL Genetics.

At this time, Diatherix Eurofins cannot accept specimens from the state of New York.

For more information please visit: eurofins-diatherix-covid-19.com

About Diatherix Eurofins

Diatherix Eurofins utilizes TEM-PCR™ (Target Enriched Multiplex Polymerase Chain Reaction), an innovative proprietary molecular technology, to deliver high throughputone-day results. TEM-PCR™ was designed to overcome the challenges that exist with conventional laboratory methods, while identifying bacteria regardless of recent antibiotic use, and difficult-to-culture pathogens. The benefits to clinicians include reduced antibiotic utilization, improved patient outcomes, cost reduction and avoidance, and improved patient satisfaction.

About Eurofins – a global leader in bio-analysis

Eurofins Scientific, through its subsidiaries (hereinafter "Eurofins" or "the Group"), believes it is a global leader in food, environmental, pharmaceutical and cosmetics products testing and in agroscience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric clinical diagnostic testing. With over 47,000 staff across a network of more than 900 independent companies in over 50 countries generally specialised by end client markets and operating more than 800 laboratories, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services. The Group's objective is to provide customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international companies in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

SOURCE Diatherix Eurofins

Did you like this article?